Featured Research

from universities, journals, and other organizations

Obesity An Advantage In Maintenance Hemodialysis Patients, Study Finds

Date:
December 10, 2006
Source:
Blackwell Publishing Ltd.
Summary:
Despite significant improvements in dialysis treatments, currently over 20 percent of the 350,000 maintenance hemodialysis patients in the United States die each year. A study published in Hemodialysis International finds that this high mortality rate may be attributed to malnutrition.

Despite significant improvements in dialysis treatments, currently over 20% of the 350,000 maintenance hemodialysis (MHD) patients in the United States die each year. A study published in Hemodialysis International finds that this high mortality rate may be attributed to malnutrition.

MHD patients experience what has been termed the “obesity paradox,” wherein obesity is associated with increased chance of survival. “A larger body fat mass as seen in obesity probably represents protective reserves that may mitigate the adverse effects of malnutrition in patients,” according to Kamyar Kalantar-Zadeh M.D., author of the study.

MHD patients tend to have a high degree of protein-energy malnutrition and inflammation. The combination of these two conditions, termed Kidney Disease Wasting (KDW), leads to increased risk of death. Conversely, it has been shown that an increase in protein intake yields the greatest survival in patients.

The study suggests that improved diet as well as appetite-stimulating agents may be a way to improve nutrition and, consequently, outcome in MHD patients. Understanding the factors that lead to KDW will be the key to improving survival in MHD patients, as well as in the 20 to 40 million Americans who exhibit similar risk-factor paradoxes such as those with chronic heart failure, AIDS, rheumatoid arthritis and malignancy.


Story Source:

The above story is based on materials provided by Blackwell Publishing Ltd.. Note: Materials may be edited for content and length.


Cite This Page:

Blackwell Publishing Ltd.. "Obesity An Advantage In Maintenance Hemodialysis Patients, Study Finds." ScienceDaily. ScienceDaily, 10 December 2006. <www.sciencedaily.com/releases/2006/11/061114185223.htm>.
Blackwell Publishing Ltd.. (2006, December 10). Obesity An Advantage In Maintenance Hemodialysis Patients, Study Finds. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2006/11/061114185223.htm
Blackwell Publishing Ltd.. "Obesity An Advantage In Maintenance Hemodialysis Patients, Study Finds." ScienceDaily. www.sciencedaily.com/releases/2006/11/061114185223.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins